Menu

News and insights

Updates from Syncona and our portfolio companies

Filter by:

Type

Topic

Company

Reset
Quell

19.05.2020

Quell Corporate Presentation

Download (1.06Mb)
Quell

08.04.2020

Quell Therapeutics Enters a Collaborative Research Agreement with the Hannover Medical School

London and Hannover – April 7 2020 – Quell Therapeutics, a biotechnology company developing engineered T regulatory (Treg) cell therapies, today announced that the company has entered into a collaborative research agreement with Hannover Medical School (MHH). Under the terms of the agreement, Quell Therapeutics will collaborate in joint research with MHH to accelerate the discovery and validation of multiple Chimeric Antigen Receptor (CAR)-Treg cell therapies.
Quell

15.10.2019

Founding Quell Therapeutics

Syncona’s Chief Executive, Martin Murphy and Syncona Partner, Elisa Petris talk through the process for founding our innovative cell therapy company, Quell Therapeutics.
Quell

15.10.2019

Quell Therapeutics and an emerging area of cell therapy

Syncona speaks to one of Quell Therapeutics’ academic founders, Alberto Sanchez-Fueyo, about his career, the potential of T-regulatory cells and his vision for the business.
Quell

23.09.2019

Quell Therapeutics named a “Fierce 15“ Company by FierceBiotech

Quell Therapeutics, a biotechnology company focused on developing engineered T regulatory (Treg) cell therapies, announces that it has been named by FierceBiotech as one of 2019’s Fierce 15 biotechnology companies, designating it as one of the most promising private biotechnology companies in the industry.
Quell

13.06.2019

Quell Therapeutics, founded by Syncona Ltd, appoints Chief Executive

Building a team of leading experts in the field of Regulatory T cell-based therapy and biology London, 13 June 2019 – Quell Therapeutics, a biotechnology company focused on developing engineered T regulatory (Treg) cell therapies, announces the appointment of Iain McGill, as Chief Executive. Iain is a leading pharmaceutical executive with extensive relevant experience having spent the majority of his 25 years in the industry in the area of solid organ and cell transplantation.